Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

letion of the Fundraising.  

In addition, Annette Clancy has decided to step down as Non-executive Director at Admission.

Intentions of the Directors and the Proposed Director in relation to the Subscription

Several of the Directors and the Proposed Director have agreed to subscribe for Subscription Shares as follows:

Director     Number of Subscription Shares    

Anthony Sedgwick    2,000,000

Max Herrmann    2,000,000

Proposed Director

Ali Mortazavi    20,000,000

The Directors do not intend to acquire Open Offer Shares pursuant to their respective Open Offer Entitlements.

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

2012

Record Date and time for entitlements under the Open Offer    5.00 p.m. on 10 July

Existing Ordinary Shares marked 'ex' by the London Stock Exchange    8.00 a.m. on 12 July

Announcement of the Fundraising and posting of Circular, Application Forms
and Form of Proxy    12 July

Open Offer Entitlements credited to

stock accounts in CREST of Qualifying CREST Shareholders    8.00 a.m. on 13 July

Recommended latest time for requesting withdrawal of Open

Offer Entitlements from CREST    4.30 p.m. on 19 July

Latest time for depositing Open Offer Entitlements
into CREST    3.00 p.m. on 20 July

Latest time and date for splitting of Application Forms

(to satisfy bona fide market claims only)    3.00 p.m. on 25 July

Latest time and date for receipt of Forms of Proxy and electronic proxy

appointments via the CREST system    10.00 a.m. on 29 July

Latest time and date for receipt of completed Application

Forms and payment in full under the Open Offer or settlement

of relevant CREST instruction (as appropriate)    11.00 a.m. on
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Custom Learning Designs, Inc.(CLD) unveils the ... Tin Can API combined with its own proprietary ... leading developer of training content and solutions for ... , Tin Can API is a cost-effective learning ... more accurately measure the Return on Education (ROE) ...
(Date:5/21/2013)... ISTANBUL , May 21, 2013 ...  European Dialysis and Transplant Association) is the biggest congress ... renal replacement therapy. Nearly 10,000 participants are in ... discuss the latest research findings. New pioneering studies have ... al. "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ...
(Date:5/21/2013)... 21, 2013 According to a ... http://www.transparencymarketresearch.com ) "Biochip Products and Services Market (Microarrays, Reagents, ... Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the market ... is expected to grow at a CAGR of 10.1% ... of USD 4.7 billion in 2018. Browse ...
(Date:5/21/2013)...  MacroGenics, Inc. today announced that an abstract ... Fc-modified chimeric monoclonal antibody (MAb), in patients with ... be presented at the 2013 Annual Meeting of ... Developmental Therapeutics - Immunotherapy Oral Abstract Session on ... The presentation will describe the results of a ...
Breaking Biology Technology:CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... Campbell Alliance, the,leading management consulting firm specializing in ... Managed Markets Practice will,take a leadership role at ... Modeling Strategies hosted by the Center for Business,Intelligence ... 10 through 11 at,the Doubletree Hotel in Philadelphia, ...
... Biology 2008 Meeting, SAN DIEGO, April 3, ... Biothera, reduced the incidence of fever,and eliminated the ... school due to,the cold-like symptoms, researchers reported today ... Cox, Ph.D., Vice President of Research & Development ...
... by over ... 100%, year-over-year, ... ), manufacturer and marketer of state-of-the-art cardiac,surgery products and services, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), The Company currently expects ...
Cached Biology Technology:Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies 2Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies 3Wellmune WGP(R) Supplementation Alleviates Duration, Severity and 'Down Time' Due to Cold Symptoms 2Wellmune WGP(R) Supplementation Alleviates Duration, Severity and 'Down Time' Due to Cold Symptoms 3ATS Medical Expects First Quarter Revenue of $14.6 to $14.8 Million 2ATS Medical Expects First Quarter Revenue of $14.6 to $14.8 Million 3
(Date:5/20/2013)... University of Minnesota Medical School researchers from the ... the University,s Brain Tumor Program, have developed a new ... that allow them to discover new genes and gene ... was published this week in the journal Nature ... researchers in the lab of David Largaespada, Ph.D., professor ...
(Date:5/20/2013)... DIEGO (May 20, 2013) - A novel ... headline the groundbreaking research that will be unveiled at ... Conference (NBC). The meeting takes place Monday, May 20 ... Hotel and Marina. , "The main goal of ... fight against a pathogen that causes the disease", explained ...
(Date:5/19/2013)... Davis have engineered a strain of photosynthetic cyanobacteria to ... their findings today at the 113th General Meeting of ... we used synthetic biology approaches to probe and rewire ... for growth) cyanobacterial metabolism for the ability to grow ... on the study. He is part of Shota ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2Germ-fighting vaccine system makes great strides in delivery 2
... Market, Stantum,s SMK Series Will Let Vendors, ... SAN DIEGO, Sept. 23 Stantum Technologies,( ... today introduced a demo, evaluation and development board ... lets,users simultaneously move an unlimited number of fingers, ...
... 2008 A new study finds that environmental restoration ... study, published in Restoration Ecology, maintains that ... practice, more research should be done on whole ecosystems ... taking advantage of large restoration sites by conducting large-scale ...
... aromatase inhibitors to treat breast cancer or prevent its ... dietary supplement, researchers report. Genistein, a soy isoflavone ... can negate the effectiveness of aromatase inhibitors, which are ... promote tumor growth in some types of breast cancer. ...
Cached Biology News:Stantum Offering Demo, Evaluation & Development Board Based on Its Patented Resistive Multi-Touch Technology 2Lack of large-scale experiments slows progress of environmental restoration 2The dietary supplement genistein can undermine breast cancer treatment 2The dietary supplement genistein can undermine breast cancer treatment 3